Jaguar Gene Therapy Closes $139 Million Series B Funding Co-led by Eli Lilly and Company and Deerfield Management

Jaguar Gene Therapy Closes $139 Million Series B Funding Co-led by Eli Lilly and Company and Deerfield Management

Jaguar Gene Therapy, a company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, announced on April 13th that it has closed a $139 million Series B funding co-led by Eli Lilly and Company and Deerfield Management. Also participating in the round were ARCH Venture Partners, co-founded by Robert Nelsen and one of the largest early-stage technology venture firms in the United States, Goldman Sachs, and Nolan Capital, the investment fund of former AveXis CEO and current Jaguar Executive Chairman Sean P. Nolan. Led by former AveXis leadership, Jaguar leverages a proven management team with the expertise to ...
Read More
Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas

Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas

Sanofi announced on April 09th that it has acquired Tidal Therapeutics, a privately owned, pre-clinical stage biotech company with a novel mRNA-based approach for in vivo reprogramming of immune cells. The new technology platform will expand Sanofi’s research capabilities in both immuno-oncology and inflammatory diseases, while likely having broad applicability to other disease areas as well. Sanofi acquired Tidal Therapeutics for an upfront payment of $160 million and up to $310 million upon achievement of certain milestones. Tidal Therapeutics utilizes a novel mRNA-based approach to in vivo reprogramming of immune cells. The technology is based on proprietary nanoparticles that deliver mRNA (messages) to reprogram ...
Read More
Eloxx Acquires Zikani with Hopes to Rule the RNA Wave for Rare Disease

Eloxx Acquires Zikani with Hopes to Rule the RNA Wave for Rare Disease

Eloxx Pharma has experienced a string of changes over the past year, coming to a head with today’s announcement that the company will be acquiring early-stage biotech Zikani Therapeutics in an all-stock deal.  With preliminary Phase II results for lead cystic fibrosis drug ELX-02 expected soon, Eloxx is banking on the acquisition positioning the combined company as a leader in the ribosomal RNA-targeted therapies field. Stockholders of Zikani will receive 7.6 million shares of Eloxx, owning around 16% of the combined company. In February 2020, Eloxx was already shaking things up with leadership, replacing its CEO by promoting its chief operating officer to the role and tapping the CMO to fill the vacant chairman seat. Now, under the terms of this deal, Zikani’s president and CEO, Sumit Aggarwal, will take the helm at Eloxx. Additionally, Zikani’s CSMO, Vijay Modur, will head up Eloxx’s R&D.  For ...
Read More
FDA approves first CAR-T cell therapy for multiple myeloma

FDA approves first CAR-T cell therapy for multiple myeloma

The Food and Drug Administration approved on March 02nd the first CAR-T cell therapy for multiple myeloma, expanding use of the powerful but complex-to-manufacture treatments beyond leukemia and lymphoma, two other blood cancers for which several other cell-based drugs are already cleared. Called Abecma, the newly approved therapy is for patients who have received at least four previous multiple myeloma medicines, including standard drugs like Revlimid and Darzalex. Clinical testing showed three-quarters of participants responded to treatment with Abecma, about a third of whom went into remission.Abecma was developed by Bluebird bio and Bristol Myers Squibb, which acquired rights through its buyout ...
Read More
Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance

Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance

Evotec SE announced on March 22nd that the Company has entered into a multi-RNA target alliance with Takeda Pharmaceutical Company Limited (“Takeda”) with the goal to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches. Evotec and Takeda will jointly identify and develop small molecules targeting a range of RNA targets aligned with Takeda’s research and development areas. The collaboration will leverage Evotec’s extensive RNA targeting platform to optimally identify promising RNA sequences to target with small molecule ligands that can be developed into potentially first-in-class therapeutics. Under ...
Read More
Consortium led by eTheRNA immunotherapies Awarded EU Commission TIGER Grant of EUR 6.9 million

Consortium led by eTheRNA immunotherapies Awarded EU Commission TIGER Grant of EUR 6.9 million

eTheRNA immunotherapies NV ('eTheRNA'), a clinical-stage company developing mRNA-based immunotherapies as off-the shelf products for the treatment of cancer and infectious diseases, announced on March 22nd the award of a TIGER grant of EUR 6.9 million from the EU commission. The grant was awarded to a consortium led by eTheRNA and will be used to accelerate the development of a novel, potentially best-in-class therapeutic mRNA cancer vaccine for treating recurrent/metastatic Human Papillomavirus strain 16 positive (HPV16+) cancers such as head and neck cancer, cervical cancer andanogenital cancer. eTheRNA's mission is to develop mRNA-based immunotherapies as off-the-shelf products for the treatment of cancer and infectious ...
Read More

(no title)

Buy an Essay Online on Buy Essay Club Today students get dozens of various tasks. They simply do not have enough time to do all of them because of the great academic overload. Essay writing – one would say it is a simple task. But it is impossible to find the possibility, time and inspiration to do all tasks according to deadlines.helloworld.com To buy essay is a good way out. Our company offers to buy essays online. We work 24 hours every day for you writing papers without any mistakes, plagiarism or topic discrepancy. You can buy essays right now ...
Read More

Jaguar Gene Therapy Closes $139 Million Series B Funding Co-led by Eli Lilly and Company and Deerfield Management

Jaguar Gene Therapy Closes $139 Million Series B Funding Co-led by Eli Lilly and Company and Deerfield Management

Jaguar Gene Therapy, a company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, announced on April 13th that it has closed a $139 million Series B funding co-led by Eli Lilly and Company and Deerfield Management. Also participating in the round were ARCH Venture Partners, co-founded by Robert Nelsen and one of the largest early-stage technology venture firms in the United States, Goldman Sachs, and Nolan Capital, the investment fund of former AveXis CEO and current Jaguar Executive Chairman Sean P. Nolan. Led by former AveXis leadership, Jaguar leverages a proven management team with the expertise to ...
Read More
Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas

Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas

Sanofi announced on April 09th that it has acquired Tidal Therapeutics, a privately owned, pre-clinical stage biotech company with a novel mRNA-based approach for in vivo reprogramming of immune cells. The new technology platform will expand Sanofi’s research capabilities in both immuno-oncology and inflammatory diseases, while likely having broad applicability to other disease areas as well. Sanofi acquired Tidal Therapeutics for an upfront payment of $160 million and up to $310 million upon achievement of certain milestones. Tidal Therapeutics utilizes a novel mRNA-based approach to in vivo reprogramming of immune cells. The technology is based on proprietary nanoparticles that deliver mRNA (messages) to reprogram ...
Read More
Eloxx Acquires Zikani with Hopes to Rule the RNA Wave for Rare Disease

Eloxx Acquires Zikani with Hopes to Rule the RNA Wave for Rare Disease

Eloxx Pharma has experienced a string of changes over the past year, coming to a head with today’s announcement that the company will be acquiring early-stage biotech Zikani Therapeutics in an all-stock deal.  With preliminary Phase II results for lead cystic fibrosis drug ELX-02 expected soon, Eloxx is banking on the acquisition positioning the combined company as a leader in the ribosomal RNA-targeted therapies field. Stockholders of Zikani will receive 7.6 million shares of Eloxx, owning around 16% of the combined company. In February 2020, Eloxx was already shaking things up with leadership, replacing its CEO by promoting its chief operating officer to the role and tapping the CMO to fill the vacant chairman seat. Now, under the terms of this deal, Zikani’s president and CEO, Sumit Aggarwal, will take the helm at Eloxx. Additionally, Zikani’s CSMO, Vijay Modur, will head up Eloxx’s R&D.  For ...
Read More
FDA approves first CAR-T cell therapy for multiple myeloma

FDA approves first CAR-T cell therapy for multiple myeloma

The Food and Drug Administration approved on March 02nd the first CAR-T cell therapy for multiple myeloma, expanding use of the powerful but complex-to-manufacture treatments beyond leukemia and lymphoma, two other blood cancers for which several other cell-based drugs are already cleared. Called Abecma, the newly approved therapy is for patients who have received at least four previous multiple myeloma medicines, including standard drugs like Revlimid and Darzalex. Clinical testing showed three-quarters of participants responded to treatment with Abecma, about a third of whom went into remission.Abecma was developed by Bluebird bio and Bristol Myers Squibb, which acquired rights through its buyout ...
Read More
Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance

Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance

Evotec SE announced on March 22nd that the Company has entered into a multi-RNA target alliance with Takeda Pharmaceutical Company Limited (“Takeda”) with the goal to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches. Evotec and Takeda will jointly identify and develop small molecules targeting a range of RNA targets aligned with Takeda’s research and development areas. The collaboration will leverage Evotec’s extensive RNA targeting platform to optimally identify promising RNA sequences to target with small molecule ligands that can be developed into potentially first-in-class therapeutics. Under ...
Read More
Consortium led by eTheRNA immunotherapies Awarded EU Commission TIGER Grant of EUR 6.9 million

Consortium led by eTheRNA immunotherapies Awarded EU Commission TIGER Grant of EUR 6.9 million

eTheRNA immunotherapies NV ('eTheRNA'), a clinical-stage company developing mRNA-based immunotherapies as off-the shelf products for the treatment of cancer and infectious diseases, announced on March 22nd the award of a TIGER grant of EUR 6.9 million from the EU commission. The grant was awarded to a consortium led by eTheRNA and will be used to accelerate the development of a novel, potentially best-in-class therapeutic mRNA cancer vaccine for treating recurrent/metastatic Human Papillomavirus strain 16 positive (HPV16+) cancers such as head and neck cancer, cervical cancer andanogenital cancer. eTheRNA's mission is to develop mRNA-based immunotherapies as off-the-shelf products for the treatment of cancer and infectious ...
Read More

(no title)

Buy an Essay Online on Buy Essay Club Today students get dozens of various tasks. They simply do not have enough time to do all of them because of the great academic overload. Essay writing – one would say it is a simple task. But it is impossible to find the possibility, time and inspiration to do all tasks according to deadlines.helloworld.com To buy essay is a good way out. Our company offers to buy essays online. We work 24 hours every day for you writing papers without any mistakes, plagiarism or topic discrepancy. You can buy essays right now ...
Read More
Jaguar Gene Therapy Closes $139 Million Series B Funding Co-led by Eli Lilly and Company and Deerfield Management

Jaguar Gene Therapy Closes $139 Million Series B Funding Co-led by Eli Lilly and Company and Deerfield Management

Jaguar Gene Therapy, a company accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases, announced on April 13th that it has closed a $139 million Series B funding co-led by Eli Lilly and Company and Deerfield Management. Also participating in the round were ARCH Venture Partners, co-founded by Robert Nelsen and one of the largest early-stage technology venture firms in the United States, Goldman Sachs, and Nolan Capital, the investment fund of former AveXis CEO and current Jaguar Executive Chairman Sean P. Nolan. Led by former AveXis leadership, Jaguar leverages a proven management team with the expertise to ...
Read More
Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas

Sanofi acquires Tidal Therapeutics, adding innovative mRNA-based research platform with applications in oncology, immunology, and other disease areas

Sanofi announced on April 09th that it has acquired Tidal Therapeutics, a privately owned, pre-clinical stage biotech company with a novel mRNA-based approach for in vivo reprogramming of immune cells. The new technology platform will expand Sanofi’s research capabilities in both immuno-oncology and inflammatory diseases, while likely having broad applicability to other disease areas as well. Sanofi acquired Tidal Therapeutics for an upfront payment of $160 million and up to $310 million upon achievement of certain milestones. Tidal Therapeutics utilizes a novel mRNA-based approach to in vivo reprogramming of immune cells. The technology is based on proprietary nanoparticles that deliver mRNA (messages) to reprogram ...
Read More
Eloxx Acquires Zikani with Hopes to Rule the RNA Wave for Rare Disease

Eloxx Acquires Zikani with Hopes to Rule the RNA Wave for Rare Disease

Eloxx Pharma has experienced a string of changes over the past year, coming to a head with today’s announcement that the company will be acquiring early-stage biotech Zikani Therapeutics in an all-stock deal.  With preliminary Phase II results for lead cystic fibrosis drug ELX-02 expected soon, Eloxx is banking on the acquisition positioning the combined company as a leader in the ribosomal RNA-targeted therapies field. Stockholders of Zikani will receive 7.6 million shares of Eloxx, owning around 16% of the combined company. In February 2020, Eloxx was already shaking things up with leadership, replacing its CEO by promoting its chief operating officer to the role and tapping the CMO to fill the vacant chairman seat. Now, under the terms of this deal, Zikani’s president and CEO, Sumit Aggarwal, will take the helm at Eloxx. Additionally, Zikani’s CSMO, Vijay Modur, will head up Eloxx’s R&D.  For ...
Read More
FDA approves first CAR-T cell therapy for multiple myeloma

FDA approves first CAR-T cell therapy for multiple myeloma

The Food and Drug Administration approved on March 02nd the first CAR-T cell therapy for multiple myeloma, expanding use of the powerful but complex-to-manufacture treatments beyond leukemia and lymphoma, two other blood cancers for which several other cell-based drugs are already cleared. Called Abecma, the newly approved therapy is for patients who have received at least four previous multiple myeloma medicines, including standard drugs like Revlimid and Darzalex. Clinical testing showed three-quarters of participants responded to treatment with Abecma, about a third of whom went into remission.Abecma was developed by Bluebird bio and Bristol Myers Squibb, which acquired rights through its buyout ...
Read More
Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance

Evotec and Takeda enter strategic RNA targeting drug discovery and development alliance

Evotec SE announced on March 22nd that the Company has entered into a multi-RNA target alliance with Takeda Pharmaceutical Company Limited (“Takeda”) with the goal to discover and develop RNA targeting small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches. Evotec and Takeda will jointly identify and develop small molecules targeting a range of RNA targets aligned with Takeda’s research and development areas. The collaboration will leverage Evotec’s extensive RNA targeting platform to optimally identify promising RNA sequences to target with small molecule ligands that can be developed into potentially first-in-class therapeutics. Under ...
Read More
Consortium led by eTheRNA immunotherapies Awarded EU Commission TIGER Grant of EUR 6.9 million

Consortium led by eTheRNA immunotherapies Awarded EU Commission TIGER Grant of EUR 6.9 million

eTheRNA immunotherapies NV ('eTheRNA'), a clinical-stage company developing mRNA-based immunotherapies as off-the shelf products for the treatment of cancer and infectious diseases, announced on March 22nd the award of a TIGER grant of EUR 6.9 million from the EU commission. The grant was awarded to a consortium led by eTheRNA and will be used to accelerate the development of a novel, potentially best-in-class therapeutic mRNA cancer vaccine for treating recurrent/metastatic Human Papillomavirus strain 16 positive (HPV16+) cancers such as head and neck cancer, cervical cancer andanogenital cancer. eTheRNA's mission is to develop mRNA-based immunotherapies as off-the-shelf products for the treatment of cancer and infectious ...
Read More

(no title)

Buy an Essay Online on Buy Essay Club Today students get dozens of various tasks. They simply do not have enough time to do all of them because of the great academic overload. Essay writing – one would say it is a simple task. But it is impossible to find the possibility, time and inspiration to do all tasks according to deadlines.helloworld.com To buy essay is a good way out. Our company offers to buy essays online. We work 24 hours every day for you writing papers without any mistakes, plagiarism or topic discrepancy. You can buy essays right now ...
Read More